INTRODUCTION

Glycyrrhiza glabra is a perennial herb, native to central and South-Western Asia, as well as to the Mediterranean region and cultivated in temperate and sub-tropical regions of the world, including Europe and Asia. The root, dried and processed, is called licorice and has a characteristic odour and sweet taste (‘licorice’ derives from the Greek words γλυκός, ‘sweet’, and ρίζα, ‘root’).

Licorice is one of the most widely used medicinal plants, found in traditional formulas since antiquity (Armanini et al., 2002; Fiore et al., 2005). The use of the plant can be traced back to ancient Assyrian, Egyptian, Chinese and Indian cultures, and was appreciated by ancient Greeks and Romans. Licorice was used in Arabic medicine during the Middle Ages, as documented by the Canone of Ibn Sina (980–1037 AD), a summary of Hippocrates and Galen’s medicine. All sources mention its use for symptoms attributable to viral respiratory tract infections such as dry cough or hoarse voice and for the symptoms of hepatitis. For the past 25 years the uses of Glycyrrhiza compounds in antiquity and traditional herbal medicine have been investigated scientifically.

The main chemical constituents of licorice root are triterpene saponins. Glycyrrhizin is the major component, with a concentration varying between 1% and 9%, depending on the species, geographical location and methods of extraction (Barnes et al., 2002; Blumenthal et al., 2000). Glycyrrhizin is a glycoside, occurring as a mixture of calcium, sodium and potassium salts of glycyrrhizinic acid (also named glycyrrhizic acid) (Fig. 1). On hydrolysis it releases two molecules of trehalose, D-glucuronic acid and the aglycone 18β-glycyrrhetinic acid (also called glycyrrhetic acid), a pentacyclic triterpene derivative of the β-amyrin type (Robbers et al., 1996; Blumenthal et al., 2000; Evans, 2002; Baltina, 2003).

The aim of this review was to summarize data from medical research into the effects of licorice-derived compounds in viral infections and corresponding in vitro data analysing the underlying mechanisms.

RESULTS

Data from studies in humans

Use of licorice in viral hepatitis. Glycyrrhizin has been used in Japan for more than 20 years as a treatment for chronic hepatitis (van Rossum et al., 1998; Shibata, 2000). Following the first preliminary reports, a large number of studies have been conducted on the effects...
of licorice extracts against viral hepatitis. In randomized controlled trials, glycyrrhizin, usually administered intravenously, induced a significant reduction of serum liver enzymes and caused an improvement in liver histology in comparison with placebo. Among the most recent studies, the effect of a formulation (Stronger Neo-Minophagen C, SNMC) containing 40 mg glycyrrhizin, administered by injection to patients with chronic viral hepatitis should be mentioned. The formulation was evaluated at different doses and frequency of administration, and the overall short-term therapeutic response consisted of a dose-dependent effect suppressing alanine aminotransferase (ALT) levels in patients with chronic viral hepatitis (Miyake et al., 2002). SNMC, although without specific activity against hepatitis virus, showed an antiinflammatory effect and was able to improve the clinical condition of patients with liver disease at various stages (Acharya et al., 1993).

Glycyrrhizin has been used to treat chronic hepatitis B virus infection, and the drug may improve liver function with occasional complete recovery from hepatitis (Takahara et al., 1994; Sato et al., 1996). Daily intravenous administration of 100 and 40 mL of the glycyrrhizin-containing preparation SNMC for 4 weeks was a safe and efficacious treatment in lowering or normalizing ALT levels in patients with chronic hepatitis B (Zhang and Wang, 2002). Intravenous administration for 1 year of glycyrrhizinic acid in patients with chronic viral hepatitis B was able to produce a positive effect on the evolution of the disease, with a 30%–40% success rate, comparable to the results obtained with interferon (Eisenburg, 1992).

In patients with chronic hepatitis C glycyrrhizin has been shown to reduce transaminase levels in a randomized phase II trial (Orient et al., 2006). Following the use of SNMC, a retrospective study was conducted in Japan in order to evaluate the effect of glycyrrhizin on hepatocellular carcinoma development (Arase et al., 1997). Of 453 patients diagnosed with chronic hepatitis C a group of 84 patients was treated with SNMC (5 mg glycyrrhizin/kg) by drip infusion to AIDS patients with high CD4/CD8 ratios before treatment. In this clinical study the count of CD4 lymphocytes and the CD4/CD8 ratio in asymptomatic carriers (AC) or patients with AIDS-related complex (ARC) showed an increase. Significant clinical improvement was achieved in almost half of the treated patients (Gotoh et al., 1987).

The results were confirmed in another study (Mori et al., 1989) in haemophilia A patients with HIV infection but with AC status. The authors found that glycyrrhizin not only possesses an inhibitory effect on HIV replication, but also has interferon-inducing and natural killer (NK)-enhancing effects. The authors concluded that the administration of glycyrrhizin to HIV-positive hemophilia patients seemed to be effective in preventing the development of AIDS by raising the number of CD4-positive T-lymphocytes (Mori et al., 1989).

Animal experiments

Effects in the influenza mouse model. The principal component of licorice, glycyrrhizin, has been evaluated experimentally in the mouse model against influenza virus (Utsunomiya et al., 1997). When mice were treated intraperitoneally with 10 mg of glycyrrhizin/kg body weight 1 day before exposure to 10 LD₅₀ (lethal dose killing 50% of animals) of the influenza virus A, 1 and 4 days after the infection, all of the animals survived over the experimental period of 21 days. Conversely, the mean survival time in control mice was 10.5 days, and there were no survivors. The grade of

Figure 1. Chemical structure of glycyrrhizinic (glycyrrhizic) acid (a) and glycyrrhetinic acid (b).
pulmonary consolidation and the virus titers in the lung tissues of infected mice treated with glycyrrhizin were significantly lower than those in the lung tissues of infected mice treated with saline. An interesting finding was that when splenic T cells from glycyrrhizin-treated mice were transferred to mice exposed to influenza virus, all the recipients survived, while no survivor was seen in recipient mice inoculated with native T cells, or with splenic B cells and macrophages from glycyrrhizin-treated mice. The administration of glycyrrhizin to infected mice in combination with anti-gamma interferon monoclonal antibody did not produce any antiviral effect. The results obtained by the authors indicated that glycyrrhizin may protect mice exposed to a lethal dose of influenza virus through the induction of interferon-gamma production by T cells (Utsonomiya et al., 1997). Other previously reported studies indicated that in mice glycyrrhizin and glycyrrehetic acid were able to induce the production of interferon (Abe et al., 1982), suggesting this as a possible mechanism of action against viral infection.

**Effects in murine herpes encephalitis.** The antiviral effect of glycyrrhizin was evaluated in murine herpes encephalitis (Sekizawa et al., 2001). Intraperitoneal administration of glycyrrhizin increased the survival rate of the animals by about 2.5 times, and the viral replication in the brain was reduced to 45.6% of the control.

**In vitro studies of antiviral effects.**

The first report of an antiviral property of licorice constituents dates to the year 1979 (Pompeii et al., 1979). Following screening investigations of plant extracts, the authors found that a component of licorice roots, identified as glycyrrhizic acid, had antiviral activity inhibiting the growth and cytopathic effect of several DNA and RNA viruses, such as vaccinia, herpes simplex type 1, Newcastle disease and vesicular stomatitis viruses *in vitro*. The drug did not affect cell activity. The concentrations of glycyrrhizic acid able to inhibit both the growth and cytopathic effects of the viruses were in the range 2–8 mM, added to infected cell cultures soon after incubation at 37°C (Pompeii et al., 1979).

**Effects on herpesviridae.** Following this landmark study glycyrrhizin was evaluated for any *in vitro* antiviral action against varicella-zoster virus (Baba and Shigeta, 1987). In human embryonic fibroblast cells inoculated with five strains of the virus, glycyrrhizin produced an inhibitory effect on viral proliferation with an IC50 (inhibitory concentration reducing activity to 50% of controls) of 0.71 μM. The selectivity index, defined as the ratio of IC50 for host-cell DNA synthesis to IC50 for virus replication, was estimated to be 30 (this value is not as high as for the most commonly used antiviral drugs, the selectivity index for acyclovir is close to 600 [Machida et al., 1995]). Pretreatment of cells with the drug 24 h before inoculation was able to inhibit replication of the virus. Incubation of the virus for 30 min with a concentration of 2.4 mM glycyrrhizin was effective in inactivating more than 99% of the virus particles, and glycyrrhizin demonstrated an additive effect with other conventional antiviral drugs such as acyclovir, and also with human beta-interferon.

In studies demonstrating the inhibition of HSV-1 by glycyrrhizic acid *in vitro* a synergism of the inhibitory effect with the endogenous antiviral substance lactoferrin was found (Lampi et al., 2001).

An effect of glycyrrhizic acid was also reported against Epstein-Barr virus (EBV), which produces infectious mononucleosis (Lin, 2003). The inhibition of EBV replication *in vitro* is dose-dependent; the IC50 values for viral inhibition and cell growth were 0.04 and 4.8 mM, respectively, and the selectivity index was 120 (Lin, 2003). It has been suggested that the drug interferes with an early step of EBV replication, possibly penetration, without any effect on viral adsorption, or inactivation (Lin, 2003). Investigation of the effects of glycyrrhizin on cytomegalovirus infection of human monocyte and human embryonic lung cell lines showed that it inhibited viral antigen expression (Numazaki et al., 1994).

**Licorice and influenza virus.** New strategies for the cure of influenza are needed, since conventional antiviral agents, such as amantadine and ribavirin, are not very effective and have toxic side effects.

Glycyrrhizic acid has been shown to inhibit the recovery of hemagglutinins from influenza virus-infected embryonated hen eggs (Pompeii et al., 1983). The substance did not affect viral viability nor impair hemagglutinating activity of the virions, but was able to affect the growth of viruses in embryonic tissues, particularly at the late viral replication steps.

A recent study (Ko et al., 2006) was conducted using Glycyrrhiza uralensis ethanol extract in a culture of A549 human bronchial epithelial cells infected with influenza virus H1N1. The extract produced an inhibitory effect on the production of RANTES, the potent chemotactic cytokine for monocytes, basophils and T cells, typically detected in nasal secretions of patients with upper respiratory tract infection, and involved in the epithelial cell-mediated inflammatory process. The licorice extract was evaluated at concentrations in the range 20–200 μg/mL; at a maximal concentration, a 97.0 ± 1.8% inhibition in RANTES production was observed (Ko et al., 2006), suggesting that compounds derived from Glycyrrhiza spp. may be beneficial for the treatment of inflammatory processes related to viral infection.

**Effects of glycyrrhizin on hepatitis viruses.** The effect of glycyrrhizin in ameliorating chronic hepatitis, as indicated by the reduction of the plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities in patients with chronic hepatitis (van Rossum et al., 2001), has been demonstrated by experimental investigations on animal cells (Shiki et al., 1992; Shibata, 2000). In hepatitis B the virustatic effect could depend on inhibition of the intrahepatic transport and sialylation of the hepatitis B-virus (HBV) surface antigen (HBsAg) observed *in vitro* (Sato et al., 1996). In isolated rat hepatocytes glycyrrhizin suppressed the release of transaminase in the presence of either anti-liver cell membrane antibody or phospholipase A2 (Shiki et al., 1992). The results indicated that the treatment of liver cells with antibody activates phospholipase A2 in cell membranes leading to disintegration of the cell membrane and cell death, which resulted in the release of transaminases. Glycyrrhizin, suppressing the increase in phospholipase A2 activity, inhibited the release of transaminases, which demonstrated its anticytolytic
effect (Shiki et al., 1992). Results of in vitro and animal (rat) studies supported further that glycyrrhizin inhibits lipid peroxidation, thereby protecting the rat hepatocytes (Kiso et al., 1984; Jeong et al., 2002). It was shown that glycyrrhizin inhibits immunemediated cytotoxicity against hepatocytes and the murine NFκB activity in the murine liver injury induced by CCl₄ ethanol. Moreover, glycyrrhizin inhibited anti-FAS antibody-induced elevation of ALT in mice (Shibata, 2000). Another group demonstrated that glycyrrhizin reduced ALT levels, steatosis and fibrosis in the mouse model of liver injury induced by CCl₄ and ethanol. This experiment showed a concomitant reduced nuclear factor-kappa B binding (Wang et al., 1998).

In vitro experiments demonstrated that glycyrrhizin suppresses the secretion of hepatitis B surface antigen (HBsAg) by inhibiting the intracellular transport of HBsAg at the trans-Golgi area after O-linked glycosylation and before sialylation (Takahara et al., 1994). Other studies confirmed that glycyrrhizin binds to hepatocytes and modifies the expression of HBV-related antigens on the hepatocytes and suppresses sialylation of HBsAg (Sato et al., 1996).

Glycyrrhizin, as an immunomodulatory agent, given intravenously in combination with lamivudine was also useful in the treatment of subacute hepatitis due to hepatitis B (Tandon et al., 2001). In 1990 Crance et al. (Crance et al., 1990) found a complete concentration-dependent inhibition of the expression of the hepatitis A virus (HAV) antigen and HAV infectivity by glycyrrhizin in the human hepatoma cell line PLC/PRF/5. The mechanism of this antiviral effect was the inhibition of the penetration and endocytosis in liver cells. Proposed mechanisms were the induction of a decrease in the negative charge on the cell surface and/or a decrease of membrane fluidity.

Licorice and HIV. Glycyrrhizin inhibited the cytopathic effect and the virus-specific antigen expression in HIV-infected MT-4 cells. Furthermore glycyrrhizin inhibited giant cell formation caused by HIV-infection in Molt-4 cells, which are sensitive to HIV and fuse to giant cells after infection, providing a parameter for determining the cytopathic effect of HIV (Ito et al., 1987; Baba et al., 1988). Glycyrrhizin sulphate was found to both inhibit cell-free viral infection and cell to cell infection (Tochikura et al., 1989). Some of these effects may be due to its ability to reduce membrane fluidity. Reduced membrane fluidity by glycyrrhizin could explain how it can inhibit cell-to-cell fusion by suppression of the formation of virological synapses (Harada, 2005). It was found that HIV-1 reverse transcriptase (rRT) functioned as an effective phosphate acceptor for recombinant human casein kinase II (rhCK-II) in vitro; this phosphorylation was inhibited by the glycyrrhetinic acid derivative, quercetin and a high dose (100 μg) of glycyrrhizin. RNA-Dependent DNA-polymerase (RDDP) activity was stimulated by about 2.5-fold after full phosphorylation of rRT by rhCK-II (Harada et al., 1998).

Recent investigations have evaluated the effect of glycyrrhizin on HIV replication in cultures of peripheral blood mononuclear cells (PBMC) from HIV-infected patients (Sasaki et al., 2002–2003). In 31% of the samples, glycyrrhizin inhibited more than 90% of HIV replication, including a non-syncytium-inducing variant of HIV (NSI-HIV). Glycyrrhizin induced the production of CC chemokine ligand (CCL)₄ and CCL₅ in a dose-dependent manner, suggesting that the drug possesses the potential to inhibit NSI-HIV by stimulating the production of beta-chemokines (Sasaki et al., 2002–2003) which compete with the chemokine receptor mediated infection of cells by HIV.

Among a variety of natural products described as anti-HIV agents, glycyrrhizin was found to have a mechanism of action which may at least in part be attributed to interference with virus–cell binding (De Clercq, 2000). More recently, an increasing quantity of data suggested that the antiviral effects of glycyrrhizin are linked to the induction of endogenous interferon gamma (Thyagarajan et al., 2002). Further, glycyrrhizin affects other cellular signalling pathways such as protein kinase II, casein kinase II and transcription factors such as activator protein1 and nuclear factor κB (Wang et al., 1998).

Licorice and SARS related coronavirus. A new coronavirus has been identified in patients with severe acute respiratory syndrome (SARS), and the disease has drawn enormous attention and caused fear worldwide since early 2003. Although the disease is now under control, the possibility of a return of the pathology has stimulated the search for a remedy. Several studies have been reported, but a specific treatment for SARS has not yet been established. Various pharmacological treatments have been suggested, such as steroids, ribavirin, interferon and also glycyrrhizin (Fujii et al., 2004; Chen et al., 2004).

Glycyrrhizin inhibits SARS-associated coronavirus (SARS-CoV) replication in Vero cells with a selectivity index of 67 (Cinatl et al., 2003). In addition to inhibition of virus replication, glycyrrhizin is able to inhibit adsorption and penetration of the virus during the early steps of the replicative cycle. The activity of glycyrrhizin is lower when added during the adsorption period than after virus adsorption (EC₅₀ is 600 μg/L vs 2400 μg/L, respectively). Glycyrrhizin has been found to be most effective when given both during and after the adsorption period. The mechanism of the activity of glycyrrhizin against SARS-CoV is unclear. The studies from Cinatl et al. (2003) show that glycyrrhizin induces nitrous oxide synthase in Vero cells and that virus replication is inhibited when a nitrous oxide donor (DETA Nonoate) is added to the culture medium.

Since glycyrrhizin was shown to be able to inhibit SARS-CoV replication in vitro, the activity of several glycyrrhizic acid derivatives was evaluated (Hoever et al., 2005). The introduction of 2-acetamido-beta-D-glucopyranosylamine into the glycoside chain of glycyrrhizin produced a 10-fold increase of the anti-SARS-CoV activity. Other compounds, such as amides and conjugates of glycyrrhizin with two amino acid residues presented up to 70-fold increased activity against the virus (Hoever et al., 2005); however, the cytotoxicity increased as well in these derivatives, resulting in a decreased selectivity index.

Effects on other viruses. Glycyrrhizin was tested in vitro for antiviral activities against several pathogenic flaviviruses involved in diseases such as dengue, Japanese encephalitis, mammalian tick-borne encephalitis and yellow fever (Crance et al., 2003). Glycyrrhizin was found to be able to inhibit the replication of flaviviruses.
at high non-cytotoxic concentrations. Moreover, glycyrrhizin inhibited plaque formation in Japanese encephalitis virus at a concentration of 0.6 mmol/L at 96 h (Badam, 1997). The target for glycyrrhizin action against the vesicular stomatitis virus (VSV) has been identified as enzyme kinase P (Ohtsuki and Iahida, 1988), which is essential for the early stages of viral replication. Glycyrrhizin at low doses was found to selectively inhibit protein phosphorylation by kinase P, without any significant effect on other kinases. It has been reported that this direct binding of glycyrrhizin to the virus-associated kinase results in its inactivation and a reduction of viral infectivity (Ohtsuki and Iahida, 1988). Recently glycyrrhiza GD4, which does not contain glycyrrhizic acid was found to inhibit the cytopathic effect of respiratory syncytial virus in HeLa cells (Wang et al., 2006).

Recently, it has been demonstrated that a treatment with glycyrrhizic acid of cells latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) is able to reduce the synthesis of a viral latency protein and to induce apoptosis of infected cells (Curreli et al., 2005). This finding suggests that glycyrrhizic acid may be the key to find a novel way to interrupt latency in infected cells (Cohen, 2005).

### Potential adverse effects of treatment with glycyrrhizin.

The toxic effects of licorice extract and glycyrrhizinate compounds have been well studied and documented in humans over the past 30–40 years. Reported adverse effects of glycyrrhizin include aldosterone-like effects (pseudohyperaldosteronism), which are related to its inhibition of conversion of cortisol to cortisone (Armanini et al., 2005). This has been associated with hypokalemia, hypertension, decreased plasma renin and aldosterone levels, myopathies, oedema and/or muscle weakness in people taking excessive amounts of glycyrrhizin containing products. An acceptable daily intake avoiding these effects has been determined as 0.2 mg/kg of glycyrrhizin. Heavy consumption of licorice has also been associated with an increased risk of preterm birth in cross-sectional and retrospective studies (Isbrucker and Burdock, 2006).

### CONCLUSIONS

The threat to global public health by pandemics of viral diseases like those induced by influenza and HIV viruses requires the urgent evaluation of herbal drugs which showed promise in traditional herbal medicine. The lack of effective drugs against influenza virus and the increasing problem with multiresistance in HIV infection makes Glycyrrhiza sp.-derived compounds important candidates for drug development. The data reviewed showed that several constituents of licorice roots have a potential as effective alternatives in combating a wide variety of respiratory, hepatic and systemic viral diseases by general immune modulatory and membrane effects, as well as specific effects on enzyme activity and expression related to selected viruses (see Table 1).

In view of the safety profile established in Japanese trials in patients with viral hepatitis, randomized controlled trials and dose finding studies in the prevention and treatment of influenza virus and HIV infection are justified. Future trials need to address the potential side effects, which have been reported with licorice use, particularly in elderly people with heart disease and on diuretic medication. Further in vitro studies working on chemically modified derivatives with greater activity and increased selectivity indices are required.

### Table 1. Key studies conducted with licorice-derived compounds as antiviral agent

| Virus                  | Study subject | Principal antiviral effects and mechanisms of action                                      | Compound used                          | References                   |
|------------------------|---------------|------------------------------------------------------------------------------------------|----------------------------------------|------------------------------|
| Hepatitis B virus (HBV)| Humans        | Effective in normalizing serum transaminases; immunomodulating effect                   | Glycyrrhizin (mainly from SNMC, see text) | Takahara et al., 1994       |
|                        | Guinea-pig    | Suppression of HbsAg secretion                                                          | Glycyrrhizin                           | Sato et al., 1996           |
|                        | in vivo       | Reduction of transaminase release; anticytolytic effect                                 |                                       | Eisenburg, 1992             |
|                        | Rat hepatocytes in vitro |                                                  | Glycyrrhizin                          | Shiki et al., 1992          |
| Hepatitis C virus (HCV)| Humans        | Effective in normalizing serum transaminases; inhibition of immune-mediated cytotoxicity | Glycyrrhizin (mainly from SNMC)        | Orient et al., 2006         |
|                        |               |                                                                                         | glycyrrhetinic acid                   | Arase et al., 1997          |
|                        |               |                                                                                         |                                       | Ikeda et al., 2006          |
|                        |               |                                                                                         |                                       | Van Rossum et al., 2001     |
|                        |               |                                                                                         |                                       | Shibata, 2000               |
|                        |               |                                                                                         |                                       | Crance et al., 1990         |
| Hepatitis A virus (HAV)| Hepatoma cell line | Inhibition of virus expression                                                          | Glycyrrhizin                          |                             |

Copyright © 2007 John Wiley & Sons, Ltd.

*Phytother. Res.* **22**, 141–148 (2008)

DOI: 10.1002/ptr
## Table 1. (Continued)

| Virus                                      | Study subject            | Principal antiviral effects and mechanisms of action                                                                                                                                                                                                 | Compound used                                      | References                                                                 |
|--------------------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------------------------|
| Human immunodeficiency virus (HIV)         | Humans                   | Improved CD4/CD8 ratio; inhibition of HIV replication                                                                                                                                                                                                 | Glycyrrhizin (from SNMC)                          | Gotoh et al., 1987                                                      |
|                                            | Cell cultures            | Inhibition of cytopathic effect; inhibition of viral infection also via reduction of membrane fluidity and binding to cell; inhibition of reverse transcriptase; inhibition of viral replication; induction of IFN-γ effects on multiple signaling pathways (including protein kinase and NFκB) | Glycyrrhizin                                     | Mori et al., 1989                                                      |
| Influenza virus                            | Mice in vivo             | Improvement in survival time of animals after infection; increase of IFN-γ production                                                                                                                                                               | Glycyrrhizin                                     | Utsonomiya et al., 1997                                                 |
|                                            | Cell cultures            | Inhibition of virus growth; inhibition of inflammatory cytokines                                                                                                                                                                                     | Glycyrrhizic acid G. uralensis ethanol extract   | Abe et al., 1982                                                        |
| SARS-related coronavirus                   | Cell cultures            | Inhibition of virus replication; induction of cellular NO-synthase                                                                                                                                                                                   | Glycyrrhizin glycyrrhizic acid derivatives        | Cinatl et al., 2003                                                     |
| Herpesviridae family viruses (VZV, HSV-1, | Cell cultures            | Inhibition of virus replication                                                                                                                                                                                                                     | Glycyrrhizin glycyrrhizic acid                    | Hoever et al., 2005                                                     |
| EBS, CMV)                                  | Cell cultures            | Inhibition of virus replication; induction of cellular NO-synthase                                                                                                                                                                                   |                                                 |                                                                          |
|                                            | Mice (murine herpes encephalitis) | Increase in animal survival rate                                                                                                                                                                                                                   | Glycyrrhizin                                     |                                                                          |
| Vaccinia virus (VV)                        | Cell cultures            | Inhibition of virus growth                                                                                                                                                                                                                         | Glycyrrhizic acid                                | Pompei et al., 1979                                                     |
| Newcastle disease virus (NDV)              | Cell cultures            | Inhibition of virus growth                                                                                                                                                                                                                         | Glycyrrhizic acid                                | Pompei et al., 1979                                                     |
| Vesicular stomatitis virus (VSV)           | Cell cultures            | Inhibition of virus growth; inhibition of enzyme kinase P                                                                                                                                                                                         | Glycyrrhizic acid                                | Pompei et al., 1979                                                     |
| Flaviviruses                               | Cell cultures            | Inhibition of virus replication                                                                                                                                                                                                                     | Glycyrrhizin                                     | Crance et al., 2003                                                     |
| Respiratory syncytial virus (RSV)          | Cell cultures            | Inhibition of cytopathic effect                                                                                                                                                                                                                     | Glycyrrhizic acid (Glycyrrhiza GD4)              | Wang et al., 2006                                                       |
| Kaposi sarcoma-associated herpes virus (KSHV) | Cell cultures          | Reduction of synthesis of a viral latency protein; induction of infected cell apoptosis                                                                                                                                                               | Glycyrrhizic acid                                | Curreli et al., 2005                                                     |

References:
- Gotoh et al., 1987
- Mori et al., 1989
- Ito et al., 1987
- Baba et al., 1988
- Tochikura et al., 1989
- Harada, 2005
- Harada et al., 1998
- Sasaki et al., 2002–2003
- De Clercq 2000
- Thyagarajan et al., 2002
- Wang et al., 1998
- Utsonomiya et al., 1997
- Abe et al., 1982
- Pompei et al., 1983
- Ko et al., 2006
- Cinatl et al., 2003
- Hoever et al., 2005
- Baba and Sigeta, 1987
- Lampi et al., 2001
- Lin, 2003
- Numazaki et al., 1994
- Machida et al., 1995
- Pompei et al., 1979
- Sekizawa et al., 2001
- Pompei et al., 1979
- Pompei et al., 1979
- Ohtsuki and Iahida, 1988
- Crance et al., 2003
- Wang et al., 2006
- Curreli et al., 2005
- Cohen, 2005
ANTIVIRAL EFFECTS OF GLYCYPHRIZA SPECIES

REFERENCES

Abe N, Ebina T, Ishida N. 1982. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Biol 26: 535–539.

Acharya SK, Dasarathy S, Tandon A, Joshi YK, Tandon BN. 1993. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res 98: 68–74.

Arase Y, Ikeda H, Murashima N et al. 1997. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79: 1494–1500.

Armanini D, Fiore C, Bielenberg J, Ragazzi E. 2005. Licorice (Glycyrrhiza glabra). In Encyclopedia of Dietary Supplements, Coates P (ed.). Marcel Dekker Inc.: New York, 391–399.

Armanini D, Fiore C, Matteerello MJ, Bielenberg J, Palermo M. 2002. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabet 110: 257–261.

Baba M, De Clercq E. 2000. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV). Antiviral Res 10: 289–308.

Baba M, Shigeta S. 1987. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res 7: 99–107.

Badam L. 1997. In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhetic acid (Sigma) on Hepatitis B virus. Encephalitis 5: 95–98.

Baltina LA. 2003. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr Med Chem 10: 155–171.

Barres J, Anderson LAA, Phillipson JD. 2002. Herbal Medicines 2nd edn. Pharmaceutical Press: London, 325–329.

Blumenthal M, Goldberg A, Brinckmann J, Foster S. 2000. Herbal Pharmacology and Toxicology of Glycyrrhizin. Reg Toxicol Pharmacol 31(3): 155–159.

Chen F, Chan KH, Jiang Y et al. 2004. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31: 69–75.

Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. 2003. Glycyrrhizin, an active component of liquorice root, and replication of SARS-associated coronavirus. Lancet 361: 2045–2046.

Cohen JI. 2005. Licking latency with licorice. J Clin Invest 115: 591–593.

Crance JM, Biziagos E, Passagot J, van Cuyck-Gandre H, Garin D, Scaramozzino N. 2003. Interferon induction by glycyrrhizin in chronic hepatitis C patients. J Med Chem 46: 157–162.

Deloince R. 1990. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 31: 155–159.

Doerr HW. 2003. Glycyrrhizin, an active component of licorice. In: Nutril Nutraceuticals. Williams & Wilkins: Baltimore, 25–35.

Eisenburg J. 1992. Treatment of chronic hepatitis B Part 2: Effect of glycyrrhizin acid on the course of illness. Fortschrift Med 110: 395–398.

Evans WC. 2002. Trease and Evans Pharmacognosy, 15th edn. Saunders: Edinburgh-London-New York, 299–302.

Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. 2005. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 99: 317–324.

Fujii T, Nakamura T, Iwamoto A. 2004. Current concepts in SARS treatment. J Infect Chemother 10: 1–7.

Gotoh Y, Tada K, Yamada M et al. 1997. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res 7: 99–107.

Ikeda K, Arase Y, Kobayashi Y et al. 2006. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: A cohort study of 1249 patients. Dig Dis Sci 51: 603–609.

Ishibuchi RA, Burdon GA. 2006. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Reg Toxicol Pharmacol 46: 167–192.

Ito M, Nakashima H, Baba M et al. 1987. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus. Antivir Res 7: 127–137.

Ikeda K, Arase Y, Kobayashi Y et al. 2006. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: A cohort study of 1249 patients. Dig Dis Sci 51: 603–609.

Ishibuchi RA, Burdon GA. 2006. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Reg Toxicol Pharmacol 46: 167–192.

Ito M, Nakashima H, Baba M et al. 1987. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus. Antivir Res 7: 127–137.

Jeong HG, You HJ, Park SJ et al. 2002. Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmaco Res 46: 221–227.

Kiso Y, Tohkim H, Hattori M, Sakamoto T, Namba T. 1984. Mechanism of antitumor and antiviral activity of glycyrrhizin. I: Effect on free radical generation and lipid peroxidation. Planta Med 50: 298–302.

Ko HC, Wei BL, Chiu WF. 2006. The effect of medicinal plants used in Chinese folk medicine on RANTES secretion by virus-infected human epithelial cells. J Ethnopharmacol 107: 205–210.

Kumada H. 2002. Long-term treatment of chronic hepatitis C with glycyrrhizin [Stronger Neo-Minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 (suppl 1): 94–100.

Lampi G, Deidda D, Pinza M, Pompei R. 2001. Enhancement of the anti-inflammatory activity of glycyrrhizin by glycyrrhetinic acid derivate. Biol Pharm Bull 24: 323–329.

Machida H, Nishitani M, Watanabe Y, Yoshimura Y, Kano F, Sakata S. 1995. Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues. Microbiol Biol 39: 201–206.

Miyake K, Tango T, Ota Y et al. 2002. Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. J Gastroenterol Hepatol 17: 1198–1204.

Morii K, Sakai H, Suzuki S et al. 1989. Effects of glycyrrhizin (SNMC: stronger Neo-Minophagen C) in hemophila patients with HIV infection. Tohoku J Exp Med 158: 25–35.

Numazaki K, Nagata N, Sato T, Chiba S. 1994. Effect of glycyrrhizin, cyclosporin A, and tumor necrosis factor alpha on infection of U937 and MRC-5 cells by human cytomegalovirus. J Leukoc Biol 58: 24–28.

Ohtsuki I, Iahida N. 1998. Inhibitory effect of glycyrrhizin on polypeptide phosphorylation by polypeptide-dependent protein kinase (kinase P) in vitro. Biochem Biophys Res Commun 157: 597–604.

Orient H, Hansen BE, Willems M et al. 2006. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomised phase II trial. J Hepatol 45: 539–546.

Pompei R, Floro M, Marcialis MA, Pani A, Loddo B. 1979. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 281: 689–690.

Pompei R, Pagli L, Ingianni A, Uccheddu P. 1983. Glycyrrhizinic acid inhibits influenza virus growth in embryonated eggs. Microbiologia 6: 247–250.

Robbers JE, Speedie MK, Tyler VE. 1996. Pharmacognosy and Pharmacobiotechnology. Williams & Wilkins: Baltimore, 55–56.

Sasaki H, Takei M, Kobayashi M, Pollard RB, Suzuki F. 2002–2003. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood...
mononuclear cells from HIV-seropositive patients. Pathobiology 70: 229–236.
Sato H, Goto W, Yamamura J et al. 1996. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 36: 171–177.
Sekizawa T, Yanagi K, Itoyama Y. 2001. Glycyrrhizin increases survival of mice with herpes simplex encephalitis. Acta Virol 45: 51–54.
Shibata S. 2000. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakagaku Zasshi 120: 849–862.
Shiki Y, Shirai K, Saito Y, Yoshida S, Mori Y, Wakashin M. 1992. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol 7: 12–16.
Takahara T, Watanabe A, Shiraki K. 1994. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. Hepatol Res 21: 601–609.
Tandon A, Tandon BN, Bhujiwala RA. 2001. Treatment of subacute hepatitis with lamivudine and intravenous glycyrrhizin: a pilot study. Hepatol Res 20: 1–8.
Thyagarajan S, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi M. 2002. Herbal medicines for liver diseases in India. J Gastroenterol Hepatol 17 (Suppl. 3): S370–S376.
Tochikura TS, Nakashima H, Yamamoto N. 1989. Antiviral agents with activity against human retroviruses. J Acquir Immune Defic Syndr 2: 441–447.
Utsonomiya T, Kobayashi M, Pollard RB, Suzuki F. 1997. Glycyrrhizin, an active component of licorice root, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother 41: 551–556.
Van Rossum TG, Vulto AG, De Man RA, Brouwer JT, Schalm SW. 1998. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12: 199–205.
Van Rossum T, Vulto A, Hop W, Schalm W. 2001. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96: 2432–2437.
Wang KY, Guo JS, Li H, Liu SL, Zern MA. 1998. Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl4 plus ethanol-induced liver cirrhosis in rats. Liver 18: 180–185.
Wang XQ, Li HY, Liu XY et al. 2006. The anti-respiratory syncytial virus effect of active compound of Glycyrrhiza GD4 in vitro. Zhang Yao Cal 29: 692–694.
Zhang L, Wang B. 2002. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res 24: 220.